v3.26.3
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
 8 Months Ended 12 Months Ended
Jun. 30, 2026
Oct. 31, 2025
Oct. 31, 2024
Income Statement [Abstract]      
Revenues (includes sales to related parties of approximately $70,000, $88,000 and $199,000, respectively) $ 5,868,000 $ 5,199,000 $ 4,620,000
Cost of revenues 1,128,000 931,000 844,000
Gross profit 4,740,000 4,268,000 3,776,000
General and administrative expenses (Including $4,697,000, $4,091,000 and $3,445,000 of stock based compensation to related parties) 10,165,000 9,654,000 9,095,000
Loss from operations (5,425,000) (5,386,000) (5,319,000)
Other income (expense)      
Gain on Sale of Exotropin interests 390,000
Interest expense (27,000) (98,000) (92,000)
Change in obligation to repurchase shares (3,000) (2,000)
Inducement expense to convert Notes payable (136,000)
Impairment of non-marketable securities in a related entity (45,000)
Other income 27,000 101,000 751,000
Net loss (5,038,000) (5,521,000) (4,705,000)
Net income attributable to the non-controlling interests 36,000
Net loss attributable to Zeo ScientifiX, Inc. $ (5,074,000) $ (5,521,000) $ (4,705,000)
Net loss per common share - basic $ (0.68) $ (0.86) $ (0.74)
Net loss per common share - diluted $ (0.68) $ (0.86) $ (0.74)
Weighted average number of common shares outstanding - basic 7,493,536 6,409,953 6,336,392
Weighted average number of common shares outstanding - diluted 7,493,536 6,409,953 6,336,392